Results 71 to 80 of about 21,372 (208)
Mechanism of homoharringtonine sensitizing venetoclax in acute myeloid leukaemia
, 2023 Acute myeloid leukemia (AML) is characterized by the uncontrolled proliferation of immature myeloid cells in bone marrow or peripheral blood. It is a heterogeneous disease with different genetic and cytogenic abnormalities.
Kwok, Tsz Ho, 郭子豪
core
British Journal of Haematology, EarlyView.Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo +3 more
wiley +1 more source
A Population Pharmacokinetics Study of Venetoclax Concomitant with Voriconazole in Patients with Hematologic Malignancies [PDF]
Jing Yang,1– 3,* Haoran Wang,1,* Dongmei Liu,1 Weijie Cao,4 Han Xing,1– 3 Peile Wang1– 3 1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People’s Republic of China; 2Henan Key ...
Yang J +5 more
core
Cell Death and DiseaseBCL-2 inhibitors such as venetoclax offer therapeutic promise in acute myeloid leukemia (AML) and other cancers, but drug resistance poses a significant challenge. It is crucial to understand the mechanisms that regulate venetoclax response.
Lixia Zhang +9 more
doaj +1 more source
British Journal of Haematology, EarlyView.Summary Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two ...
Desiree Kunadt +55 more
wiley +1 more source
Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
, 2019 Tristan Knight,1,2 Holly Edwards,3,4 Jeffrey W Taub,1–2,4 Yubin Ge2–41Division of Pediatric Hematology and Oncology, Department of Pediatrics, Children’s Hospital of Michigan, Detroit, MI, USA; 2Department of Pediatrics, Wayne State ...
Ge Y, Edwards H, Taub JW, Knight T
core
British Journal of Haematology, EarlyView.Summary Second primary cancers (SPCs) are a survivorship concern in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia (LPL/WM), but estimates may be influenced by competing mortality and surveillance. We assessed cumulative incidence, relative risk and predictors of SPCs. We studied 521 patients diagnosed with LPL/WM in Region Zealand, Denmark,
Lars Munksgaard +2 more
wiley +1 more source
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Nature Communications, 2018 BCL2-inhibitor venetoclax is used to treat relapsed/refractory chronic lymphocytic leukemia (CLL). Here, the authors show the clonal dynamics towards venetoclax resistance by performing whole-exome sequencing of 8 CLL patients undergoing venetoclax ...
Carmen D. Herling +30 more
doaj +1 more source
British Journal of Haematology, EarlyView.Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova +15 more
wiley +1 more source
HeliyonVenetoclax, a selective BCL-2 inhibitor, has shown superior efficacy in the treatment of AML. Nevertheless, some AML patients with AML1-ETO respond poorly to venetoclax treatment.
Man Li +8 more
doaj +1 more source